|View printer-friendly version|
|Quidel Receives ISO Certification|
SAN DIEGO, Jan. 3 /PRNewswire/ -- Quidel Corporation (Nasdaq: QDEL) announced today that the Company has received formal certification to ISO-9001, EN46001 and ISO-13485 standards from its Notified Body, TUV Product Service Management of Suddeutschland, based in Munich, Germany.
The certification of a quality management system to these standards is evidence of the Company's commitment to increasing the performance of its business operations through continuous improvement and sound quality systems. These systems contribute to ensuring that the development, manufacture and supply of products and services are more consistent, reliable and valuable in meeting the quality demands of the customer. The certification is also important for medical companies active in global markets, where the establishment and independent assessment of a certified quality system are required.
"We are delighted to have received this ISO Certification. This means that our customers can be assured that our systems are designed to provide quality products with superior service," said Esperanza Buckley, Senior Quality Manager, of Quidel Corporation. "We have invested significant resources in the infrastructure that governs our every-day operations to become more efficient."
Quidel Corporation discovers, develops, manufactures and markets point-of-care, rapid diagnostic tests for detection of medical conditions and illnesses. These products provide accurate, rapid and cost-effective diagnostic information for acute and chronic conditions that affect women's health throughout the phases of their lives including reproductive status, pregnancy management and osteoporosis. Quidel also provides point-of-care diagnostics for infectious diseases, including influenza A and B, strep throat, H. pylori infection, chlamydia and infectious mononucleosis. Quidel's products are sold to healthcare professionals for use in physicians' offices, clinical laboratories and pharmacies, and to consumers through organizations that provide private label, store brand products. These tests provide diagnostic information to enable rapid treatment and improve health outcomes, lower costs, and increase patient satisfaction.
This press release contains forward-looking statements regarding Quidel's future activities within the meaning of the federal securities laws. These forward-looking statements involve material risks and uncertainties. Many possible factors could affect the future results and performance of Quidel's products, such that actual results and performance may differ materially. If Quidel's products fail to perform as expected, or if there is lower consumer demand for these products than expected, Quidel's financial condition and operating results may be materially and adversely affected. Quidel's financial condition and operating results may also be materially and adversely affected by a number of other factors, including, without limitation, seasonality, adverse changes in competitive and economic conditions, actions by the Company's distributors, manufacturing and production delays or difficulties and adverse actions or delays in product reviews by the FDA. Please see the discussion of these and other factors in Quidel's annual reports on Form 10-K and subsequent quarterly reports on Form 10-Q. For more information, please visit Quidel's web site at http://www.quidel.com.